Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results

PR Newswire August 5, 2021

FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

PR Newswire August 2, 2021

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

PR Newswire July 29, 2021

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

GlobeNewswire July 7, 2021

Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

GlobeNewswire June 7, 2021

Vaxart to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2021

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

GlobeNewswire May 7, 2021

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

GlobeNewswire May 3, 2021

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 3, 2021

Vaxart to Present at the World Vaccine Congress Washington 2021

GlobeNewswire April 29, 2021

Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines

GlobeNewswire April 26, 2021

Vaxart Appoints David Wheadon, M.D., to its Board of Directors

GlobeNewswire April 23, 2021

Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans

GlobeNewswire April 22, 2021

Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 4, 2021

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 25, 2021

Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

GlobeNewswire February 24, 2021

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

GlobeNewswire February 3, 2021

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire January 29, 2021

Glancy Prongay & Murray LLP Announces Investigation of Vaxart, Inc.

Business Wire January 27, 2021

Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine

GlobeNewswire January 27, 2021